Thyrotoxic periodic paralysis
Case report and review of the literature
Keywords:
Thyrotoxicosis, Hypokalemia, Periodic paralysis, Graves’ disease, HyperthyroidismAbstract
Introduction: Thyrotoxic periodic paralysis (TPP) is a rare and potentially lethal complication of hyperthyroidism. It is characterized by sudden onset paralysis associated with hypokalemia. Management includes prompt normalization of potassium, which results in resolution of the paralysis. Definitive treatment of hyperthyroidism resolves TPP completely. Case presentation: A 23-year-old African American male patient presented to the emergency room at the University of Mississippi Medical Center, USA in November 2016 with sudden onset quadriplegia. He also endorsed a history of weight loss, palpitations, heat intolerance and tremors. The patient reported similar episodes of quadriplegia in the past, which were associated with hypokalemia and resolved with normalization of potassium levels. Physical examination was significant for exophthalmos, smooth goiter with bruit consistent with the diagnosis of Graves’ disease. Laboratory assessment showed severe hypokalemia, hypomagnesemia, suppressed thyroid stimulating hormone (TSH) and high free thyroxine (T4). Urine potassium creatinine ratio was less than one, indicating transcellular shift as the cause of hypokalemia. After normalization of potassium and magnesium, the paralysis resolved in 12 hours. He was started on methimazole. On follow up, the patient was clinically and biochemically euthyroid with no further episodes of paralysis. Take-away lesson: TPP is a rare and reversible cause of paralysis. Physicians need to be aware of the diagnostic and treatment modalities as delayed recognition in treatment could result in potential harm or unnecessary interventions.References
Okinaka S, Shizume K, Iino S, Watanabe A, Irie M, Noguchi A, et al. The association of periodic paralysis
and hyperthyroidism in Japan. J Clin Endocrinol Metab. 1957; 17(12): 1454–9. doi: 10.1210/jcem-17-12- 1454. PMID: 13481091.
Ober KP. Thyrotoxic periodic paralysis in the United States. Report of 7 cases and review of literature.
Medicine 1992; 71(3): 109-20. doi: 10.1097/00005792-199205000-00001. PMID: 1635436.
Kung AW. Clinical review: Thyrotoxic periodic paralysis: a diagnostic challenge. J Clin Endocrinol Metab.
; 91(7): 2490-5. doi: 10.1210/jc.2006-0356. PMID: 16608889.
Falhammar H, Thorén M, Calissendorff J. Thyrotoxic periodic paralysis: clinical and molecular aspects.
Endocrine. 2013; 43(2): 274-84. PMID: 22918841.
Lin SH. Thyrotoxic periodic paralysis. Mayo Clin Proc. 2005; 80(1): 99–105. doi: 10.1016/S0025- 6196(11)62965-0.
Cheng CJ, Lin SH, Lo YF, Yang SS, Hsu YJ, Cannon SC, et al. Identification and functional
characterization of Kir2.6 mutations associated with non-familial hypokalemic periodic paralysis. J Biol
Chem. 2011; 286(31): 27425–35. doi: 10.1074/jbc.M111.249656. PMID: 21665951, PMCID:
PMC3149336.
Lin SH, Chu P, Cheng CJ, Chu SJ, Hung YJ, Lin YF. Early diagnosis of thyrotoxic periodic paralysis: spot
urine calcium to phosphate ratio. Crit Care Med. 2006; 34(12): 2984-9. doi:
1097/01.CCM.0000242249.10856.49. PMID: 16971853.
Ozaki H, Mori K, Nakagawa Y, Hoshikawa S, Ito S, Yoshida K. Autonomously functioning thyroid nodule
associated with thyrotoxic periodic paralysis. Endocr J. 2008; 55(1): 113-9. doi: 10.1507/endocrj.K07E- 017. PMID: 18202530.
Alings AM, Fliers E, de Herder WW, Hofland LJ, Sluiter HE, Links TP, et al. A thyrotropin-secreting
pituitary adenoma as a cause of thyrotoxic periodic paralysis. J Endocrinol Invest. 1998; 21(10): 703-6. doi:
1007/BF03350802. PMID: 9854688.
Lee JI, Sohn TS, Son HS, Oh SJ, Kwon HS, Chang SA, et al. Thyrotoxic periodic paralysis presenting as
polymorphic ventricular tachycardia induced by painless thyroiditis. Thyroid. 2009; 19(12): 1433-4. doi:
1089/thy.2009.0253. PMID: 20001723.
Hannon MJ, Behan LA, Agha A. Thyrotoxic periodic paralysis due to excessive L-thyroxine replacement
in a Caucasian man. Ann Clin Biochem. 2009; 46(Pt 5): 423-5. doi: 10.1258/acb.2009.009012. PMID:
Laroia ST, Zaw KM, Ganti AK, Newman W, Akinwande AO. Amiodarone-induced thyrotoxicosis
presenting as hypokalemic periodic paralysis. South Med J. 2002; 95(11): 1326-8. doi: 10.1097/00007611- 200295110-00018. PMID: 12540001.
Panikkath R, Nugent K. I lost weight, but I became weak and cannot walk—a case of nutraceutical (T3)-
induced thyrotoxic periodic paralysis. Am J Ther. 2014; 21(6): e211-4. doi:
1097/MJT.0b013e318288a460. PMID: 23567793.
Lo CS, Edelman IS. Effect of triiodothyronine on the synthesis and degradation of renal cortical (Na+ +
k+)-adenosine triphosphatase. J Biol Chem. 1976; 251(24): 7834-40.
Liberman UA, Asano Y, Lo CS, Edelman IS. Relationship between Na+-dependent respiration and Na+ +
K+-adenosine triphosphatase activity in the action of thyroid hormone on rat jejunal mucosa. Biophys J.
; 27(1): 127-44. doi: 10.1016/S0006-3495(79)85207-8.
Blanco G, Mercer RW. Isozymes of the Na-K-ATPase: heterogeneity in structure, diversity in function.
Am J Physiol. 1998; 275(5 Pt 2): F633-50.
Desai-Yajnik V, Zeng J, Omori K, Sherman J, Morimoto T. The effect of thyroid hormone treatment on the
gene expression and enzyme activity of rat liver sodium-potassium dependent adenosine triphosphatase.
Endocrinology. 1995; 136(2): 629-39. doi: 10.1210/endo.136.2.7835297. PMID: 7835297.
Mulder JE. Thyroid disease in women. Med Clin North Am. 1998; 82(1): 103-25. doi: 10.1016/S0025- 7125(05)70596-4.
Chan A, Shinde R, Chow CC, Cockram CS, Swaminathan R. Hyperinsulinaemia and Na+, K+ -ATPase
activity in thyrotoxic periodic paralysis. Clinical Endocrinolog. 1994; 41: 213–6. doi: 10.1111/j.1365- 2265.1994.tb02532.x.
Azzarolo AM, Mircheff AK, Kaswan RL, Stanczyk FZ, Gentschein E, Becker L, et al. Androgen support of
lacrimal gland function. Endocrine. 1997; 6(1): 39-45. doi: 10.1007/BF02738800. PMID: 9225114.
Aggarwal R, Chugh P. Thyrotoxic periodic paralysis: a short clinical review. Int J Res Med Sci 2015; 3:
-42. doi: 10.5455/2320-6012.ijrms20150302.
Lin SH, Huang CL. Mechanism of Thyrotoxic Periodic Paralysis. J Am Soc Nephrol. 2012; 23: 985-8. doi:
1681/ASN.2012010046. PMID: 22460532, PMCID: PMC3358768.
Hsieh MJ, Lyu RK, Chang WN, Chang KH, Chen CM, Chang HS, et al. Hypokalemic thyrotoxic periodic
paralysis: clinical characteristics and predictors of recurrent paralytic attacks. Eur J Neurol. 2008; 15(6):
-64. doi: 10.1111/j.1468-1331.2008.02132.x. PMID: 18410374.
Manoukian MA, Foote JA, Crapo LM. Clinical and metabolic features of thyrotoxic periodic paralysis in
episodes. Arch Intern Med. 1999; 159(6): 601-6.
McFadzean AJ, Yeung R. Periodic paralysis complicating thyrotoxicosis in Chinese. Br Med J. 1967;
(5538): 451-5.
Satam N, More V, Shanbag P, Kalgutkar A. Fatal thyrotoxic periodic paralysis with normokalemia. Indian
J Pediatr. 2007; 74(11): 1041-3. doi: 10.1007/s12098-007-0194-8. PMID: 18057690.
Wong GW, Leung TF, Lo AF, Ahuja AT, Cheng PS. Thyrotoxic periodic paralysis in a 14-year-old boy.
Eur J Pediatr. 2000; 159(12): 934. doi: 10.1007/PL00008375. PMID: 11131357.
Shizume K, Shishiba Y, Kuma K, Noguchi S, Tajiri J, Ito K, Noh JY. Comparison of the incidence of
association of periodic paralysis and hyperthyroidism in Japan in 1957 and 1991. Endocrinol Jpn. 1992;
(3): 315-8. doi: 10.1507/endocrj1954.39.315. PMID: 1425456.
Abbas MT, Khan FY, Errayes M, Baidaa AD, Haleem AH. Thyrotoxic periodic paralysis admitted to the
medical department in Qatar. Neth J Med. 2008; 66(9): 384–8. PMID: 18931399.
Maciel RM, Lindsey SC, Dias da Silva MR. Novel etiopathophysiological aspects of thyrotoxic periodic
paralysis. Nat Rev Endocrinol. 2011; 7(11): 657-67.
Nellen H, Mercado M, Mendoza V, Villanueva S, Pérez M, Hernández A, et al. Thyrotoxic periodic
paralysis in Mexican mestizo patients: a clinical, biochemical and HLA-serological study. Arch Med Res.
; 30(1): 74-6. doi: 10.1016/S0188-0128(98)00014-1.
Elston MS, Orr-Walker BJ, Dissanayake AM, Conaglen JV. Thyrotoxic hypokalaemic periodic paralysis:
Polynesians, an ethnic group at risk. Intern Med J. 2007; 37(5): 303-7. doi: 10.1111/j.1445- 5994.2007.01313.x. PMID: 17504277.
Lapie P, Lory P, Fontaine B. Hypokalemic periodic paralysis: an autosomal dominant muscle disorder
caused by mutations in a voltage-gated calcium channel. Neuromuscul Disord. 1997; 7(4): 234-40. doi:
1016/S0960-8966(97)00435-5.
Lu KC, Hsu YJ, Chiu JS, Hsu YD, Lin SH. Effects of potassium supplementation on the recovery of
thyrotoxic periodic paralysis. Am J Emerg Med. 2004; 22(7): 544-7. doi: 10.1016/j.ajem.2004.09.016.
Birkhahn RH, Gaeta TJ, Melniker L. Thyrotoxic periodic paralysis and intravenous propranolol in the
emergency setting. J Emerg Med. 2000; 18(2): 199-202. doi: 10.1016/S0736-4679(99)00194-8.
Shayne P, Hart A. Thyrotoxic periodic paralysis terminated with intravenous propranolol. Ann Emerg Med.
; 24(4): 736-40. doi: 10.1016/S0196-0644(94)70286-1.
Yeung RT, Tse TF. Thyrotoxic periodic paralysis. Effect of propranolol. Am J Med. 1974; 57(4): 584-90.
doi: 10.1016/0002-9343(74)90010-2.
Dalan R, Leow MK. Cardiovascular collapse associated with beta blockade in thyroid storm. Exp Clin
Endocrinol Diabetes. 2007; 115(6): 392-6. doi: 10.1055/s-2007-971065. PMID: 17701886.
Published
Issue
Section
License
Copyright (c) 2021 KNOWLEDGE KINGDOM PUBLISHING
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
